Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,944.00
(
0.88%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
-2.31%
)
Bitcoin
78,160.49
(
2.40%
)
News Focus
News Focus
Post# of 257482
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122925
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 227036

Friday, 05/29/2020 4:34:43 PM

Friday, May 29, 2020 4:34:43 PM

Post# of 257482
FDA approves Tecentriq/Avastin in 1L-HCC:

https://www.businesswire.com/news/home/20200529005593/en

The approval is based on the IMbrave150 study, where Tecentriq/Avastin bested Nexavar monotherapy on OS (HR=0.58) and PFS (HR=0.59).

HCC is an indication where checkpoint inhibitors have not done especially well compared to most other solid tumors.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today